Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

Diabetes, Obesity and Metabolism - Tập 19 Số 3 - Trang 436-441 - 2017
Katherine R. Tuttle1, T. D. McKinney2, Jaime A. Davidson3, Greg Anglin4, Kristine D. Harper2, Fady T. Botros2
1Providence Health Care University of Washington Spokane Washington
2Eli Lilly and Company, Indianapolis, Indiana
3Touchstone Diabetes Center University of Texas Southwestern Medical Center Dallas Texas
4Eli Lilly Canada, Toronto, Ontario, Canada

Tóm tắt

Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin‐to‐creatinine ratio (UACR) and kidney adverse events (AEs). No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine (mean ± standard deviation values: dulaglutide vs placebo: 87.8 ± 17.7 vs 88.2 ± 17.9 mL/min/1.73 m2, P = .075; dulaglutide vs active comparators: 89.9 ± 16.7 vs 88.8 ± 16.3 mL/min/1.73 m2, P = .223; and dulaglutide vs insulin glargine: 85.9 ± 18.2 vs 83.9 ± 18.6 mL/min/1.73 m2, P = .423). Lower UACR values were observed for dulaglutide vs placebo, active comparators and insulin glargine (at 26 weeks, median [Q1‐Q3] values were: dulaglutide vs placebo: 8.0 [4.4‐20.4] vs 8.0 [4.4‐23.9] mg/g, P = .023; dulaglutide vs active comparators: 8.0 [4.4‐21.2] vs 8.9 [4.4‐27.4] mg/g, P = .013; and dulaglutide vs insulin glargine: 8.9 [4.4‐29.2] vs 12.4 [5.3‐50.5] mg/g, P = .029). AEs reflecting potential acute renal failure were 3.4, 1.7 and 7.0 events/1000 patient‐years for dulaglutide, active comparators and placebo, respectively. In conclusion, dulaglutide treatment of clinical trial participants with T2D did not affect eGFR and slightly decreased albuminuria.

Từ khóa


Tài liệu tham khảo

10.1053/j.ajkd.2006.12.005

10.1053/j.ajkd.2012.07.005

10.1053/j.ajkd.2014.08.001

10.2215/CJN.00800209

10.1002/dmrr.2810

10.7326/0003-4819-150-9-200905050-00006

10.4158/EP10215.OR

10.1053/j.ajkd.2013.03.026

10.1177/1060028013520597

10.1007/s11096-010-9423-8

10.2337/dc08-1309

10.1002/PHAR.1014

10.1111/j.1365-2125.2007.02890.x

Byetta [prescribing information]. Wilmington DE: AstraZeneca;2015.

Bydureon [prescribing information]. Wilmington DE: AstraZeneca Pharmaceuticals LP;2015.

Lyxumia [summary of product characteristics]. Paris France: Sanofi‐Aventis Group;2013.

Tanzeum [prescribing information]. Wilmington DE: GlaxoSmithKline LLC;2014.

Victoza [prescribing information]. Princeton NJ: Novo Nordisk Inc.;2016.

10.1016/j.jdiacomp.2015.04.004

10.1111/dom.12601

10.1007/s00125-016-3938-z

10.1046/j.1523-1755.2001.059002702.x

10.1093/ndt/gfq526

10.1093/ndt/gfr561

Hirai A, 2012, A novel therapeutic use of glucagon‐like peptide1 receptor agonist for the treatment of overt diabetic nephropathy in patients with type 2 diabetes. (Abstract), Diabetes, 61, A240

Mohan V, 2012, A retrospective analysis of the effect of liraglutide in Asian Indian patients with type 2 diabetes with proteinuria. (Abstract), Diabetes, 61, A569

10.1038/ki.2013.427

10.1620/tjem.231.57

10.1681/ASN.2006070778

10.1038/ki.2014.236

10.1016/S0014-2999(01)01542-4

10.1159/000094334

10.1210/jc.2003-031403

10.1210/jc.2012-3855

10.2337/dc14-1958

10.1016/j.regpep.2006.12.016

10.1152/ajprenal.00082.2009

10.1056/NEJMoa1603827

Marso SP, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med

Trulicity [prescribing information]. Indianapolis IN: Lilly USA LLC;2015.

Trulicity [summary of product characteristics]. Houten The Netherlands: Eli Lilly and Company;2014.

Thông tin
Thông tin xuất bản

Diabetes, Obesity and Metabolism

Tập 19 Số 3

436-441

Thông tin tác giả